The results of the IMpassion132 trial

Elisa Agostinetto shared on X a paper by Rebecca Dent et al. titled “IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer” in Annals of Oncology.

Authors: R. Dent, F. Andre, A. Goncalves, A. Mani, A. Swat, J. Cortes et al.   

“Out in Annals of Oncology the results of the IMpassion132 trial.

In patients with TNBC relapsed <12 months after chemotherapy/surgery for early TNBC, OS was not improved by adding atezolizumab to chemotherapy.”

Source: Elisa Agostinetto/X

Dr. Elisa Agostinetto, is a medical oncologist, specializing in breast cancer research. Trained in Milan, Italy, she currently conducts advanced research at Institut Jules Bordet – Université Libre de Bruxelles in Brussels, Belgium.

Actively engaged in professional societies like ESMO, ASCO, and BSMO, she also contributes as a young investigator in the EORTC Breast Cancer Working Group and as a Committee member of the Young Cancer Professionals within the European Cancer Organization.